GLPG - Galapagos NV ADR

GLPG - Galapagos NV ADR

https://www.glpg.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Paul Oakenfold to Join Space2Sea's Galápagos Voyage of Discovery

Benzinga • 1 month ago • score: 0.47

GALÁPAGOS ISLANDS, Ecuador, Aug. 13, 2025 /PRNewswire/ -- November 1-8, 2025 - World-renowned DJ and music producer will bring his signature sound to an intimate, fully private expedition blending exploration, science, and culture alongside Neil deGrasse Tyson, Kathryn Sullivan, Beth Shapiro, ...

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy ( RMAT ) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

GlobeNewswire • 1 month, 1 week ago • score: 0.24

Mechelen, Belgium. August 6, 2025, 7:30 CET. regulated information - inside information - Galapagos NV ( Euronext & NASDAQ: GLPG ) today announced that the United States Food and Drug Administration ( FDA ) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T ...

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy ( RMAT ) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma - Galapagos ( NASDAQ:GLPG )

Benzinga • 1 month, 1 week ago • score: 0.22

The RMAT designation was established under the U.S. 21st Century Cures Act to accelerate development and review of promising cell and gene therapies for serious or life-threatening conditions.

Tesla Posts Downbeat Earnings, Joins Community Health Systems, Chipotle Mexican Grill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Community Health Sys ( NYSE:CYH ) , Chipotle Mexican Grill ( NYSE:CMG )

Benzinga • 1 month, 3 weeks ago • score: -0.32

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Thursday. Shares of Tesla, Inc. TSLA fell sharply in pre-market trading as the company reported weaker-than-expected second-quarter financial results after market close Wednesday.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.

52W High

$33.86

52W Low

$22.36

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.03

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

322.58

EV/EBITDA (<8 favorable)

-31.50

EV/Revenue (<3 favorable)

1.18

P/S (TTM) (<3 favorable)

7.98

P/B (<3 favorable)

0.71

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

25.35%

Institutions (25–75% balanced)

22.90%

Shares Outstanding

65,897,000

Float

65,046,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

275,609,000

Gross Profit (TTM)

108,614,000

EPS (TTM)

-5.11

Profit Margin (>10% good)

-1.03%

Operating Margin (TTM) (higher better)

-0.87%

ROE (TTM) (>15% strong)

-0.10%

EPS YoY (Quarterly) (>10% good)

0.75

Revenue YoY (Quarterly) (>8% good)

-0.16

Momentum

Bearish momentum

Value

0.2127

Previous

0.2767

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025